About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NY:AZN)

162.94 -1.27 (-0.77%)
Streaming Delayed Price Updated: 11:56 AM EDT, Sep 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2 3 4 Next >
News headline image
18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right. ↗
Wall Street expects an even bigger rebound for this beaten-down biotech stock. 
Via The Motley Fool
News headline image
Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin granted Priority Review in the US for patients with muscle-invasive bladder cancer
From AstraZeneca
Via Business Wire
News headline image
Alnylam's Sell-Off Looks Ugly -- but Wall Street Still Sees a Much Brighter Picture ↗
Analysts think Alnylam could rebound strongly over the next 12 months. 
Via The Motley Fool
News headline image
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial
From AstraZeneca
Via Business Wire
News headline image
TAGRISSO® (osimertinib) demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in ADAURA Phase III trial
From AstraZeneca
Via Business Wire
News headline image
AstraZeneca COPD Drug Cuts Exacerbations as FDA Priority Review Nears ↗
Astrazeneca (NYSE:AZN) presented Phase III data for tozorakimab in chronic obstructive pulmonary disease, or COPD, at the 2026 European Respiratory Society Congress in Barcelona, reporting... 
Via MarketBeat
Topics ETFs
News headline image
IMFINZI® (durvalumab) plus tarlatamab demonstrated a statistically significant and highly clinically meaningful improvement in overall survival and progression-free survival in 1st-line extensive-stage small cell lung cancer
From AstraZeneca
Via Business Wire
News headline image
Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trials
From AstraZeneca
Via Business Wire
News headline image
ETCAMAH® (camizestrant) in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer
From AstraZeneca
Via Business Wire
News headline image
Here's Why Ionis Pharmaceuticals' Steep Sell-off Was Overdone ↗
This biotech stock looks like a great candidate to buy on the admittedly steep dip. 
Via The Motley Fool
News headline image
AstraZeneca completes global license agreement for oral EGFR inhibitor ZEGFROVY® (sunvozertinib) for lung cancer
From AstraZeneca
Via Business Wire
News headline image
Opinion: Bristol Myers Squibb Is a Buy -- but the Real Reason Why Might Surprise Investors ↗
Bristol Myers Squibb is facing down a major patent cliff, which is a problem and a huge motivating force. 
Via The Motley Fool
Topics Intellectual Property
News headline image
TEZSPIRE demonstrates positive Phase III results in eosinophilic esophagitis across both co-primary and all key secondary endpoints
From AstraZeneca
Via Business Wire
News headline image
A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity
EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:BNTX),(NYSE:AZN),(NASDAQ:MRNA),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity
A New Generation of Personalized Cancer Treatments Could Open a Multibillion-Dollar Market for Precision Oncology 
From MarketNewsUpdates.com
Via GlobeNewswire
News headline image
Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
News Provided by USA News Group on behalf of MindWalk Holdings Corp. 
From USA News Group
Via GlobeNewswire
News headline image
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial
From AstraZeneca
Via Business Wire
News headline image
TAGRISSO® (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO
From AstraZeneca
Via Business Wire
News headline image
Why the Alnylam Sell-Off Looks Overdone -- and What Investors Are Missing ↗
Yes, Alnylam has had some bad news. But the bad news isn't as horrible as many think. 
Via The Motley Fool
News headline image
Is the Reported $400 Billion AstraZeneca-Bristol Myers Squibb Megamerger a Slam Dunk -- or a Disaster Waiting to Happen? ↗
There's a good reason why AstraZeneca tanked when merger rumors hit the Street. 
Via The Motley Fool
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN
From Pomerantz LLP
Via GlobeNewswire
News headline image
Astrazeneca Q2 Earnings Call Highlights ↗
Astrazeneca (NYSE:AZN) reported first-half 2026 revenue growth of 6% at constant exchange rates, or 11% excluding the effects of generic competition on Farxiga and Brilinta, while core earnings per... 
Via MarketBeat
Topics ETFs Earnings
News headline image
Sonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement in overall survival in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers
From AstraZeneca
Via Business Wire
News headline image
AstraZeneca results: H1 and Q2 2026
From AstraZeneca
Via Business Wire
News headline image
AZN Investors Have Opportunity to Join AstraZeneca PLC Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AstraZeneca PLC- AZN
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN
From Pomerantz LLP
Via GlobeNewswire
News headline image
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions ↗
Wainua missed its Phase 3 endpoint, hitting Ionis Pharmaceuticals hard while AstraZeneca absorbed the blow easily, boosting rivals BridgeBio, Pfizer and Alnylam Pharmaceuticals. 
Via MarketBeat
News headline image
AZN Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into AstraZeneca (AZN)
From Levi & Korsinsky, LLP
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.